MDLN 8-K 2026-11-04
Medline Inc. (MDLN) 8-K dated 2026-11-04 — accession 0002046386-26-000060.
Medline Inc. (MDLN) common stock.
MDLN revenue $7.9B, +10.4% YoY
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported MDLN revenue for 2026-06-27 was $7.68B. Net income was $139.0M. Revenue was up 4.5% from 2026-03-28 to 2026-06-27.
Not investment advice. The MDLN SEC hub lists recent forms. The stock page is the research view.
- Revenue
- $7.9B
- YoY
- +10.4%
- Diluted EPS
- $0.22
- Guidance
- full year 2026 Organic Sales 2 guidance to 10.0% to 10.5% from 9.0% to 10.0% and reaffirming Adjusted EBITDA 2 guidance of $3.3 b
Why it matters
- full year 2026 Organic Sales 2 guidance to 10.0% to 10.5% from 9.0% to 10.0% and reaffirming Adjusted EBITDA 2 guidance of $3.3 b
- Medline delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business,…